111’s (YI) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

111 (NASDAQ:YI)‘s stock had its “sell (e+)” rating reaffirmed by equities researchers at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

111 Price Performance

YI stock opened at $6.93 on Friday. The stock has a market capitalization of $59.88 million, a PE ratio of -10.83 and a beta of 0.47. The company’s 50-day moving average is $8.00 and its 200-day moving average is $7.55. 111 has a 1 year low of $4.15 and a 1 year high of $12.90.

111 (NASDAQ:YI) last released its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $486.35 million for the quarter.

Hedge Funds Weigh In On 111

Several large investors have recently added to or reduced their stakes in the business. FIL Ltd purchased a new stake in 111 in the 4th quarter valued at about $450,000. Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in shares of 111 during the 4th quarter worth approximately $245,000. JPMorgan Chase & Co. increased its stake in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after purchasing an additional 305,339 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of 111 during the 1st quarter worth approximately $92,000. Finally, Deuterium Capital Management LLC purchased a new stake in shares of 111 during the 1st quarter worth approximately $81,000. Institutional investors own 21.32% of the company’s stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.